CANTA — Cantargia AB Share News
0.000.00%
Last trade - 00:00- SEK533.52m
- SEK275.49m
- SEK316.70m
Brief: Cantargia Reports Encouraging New CAN10 Toxicology Results
Brief: Cantargia: Positive Safety Data From Cirifour Study On Nadunolimab, Pembrolizumab Combination
Brief: Cantargia Reports Updated Encouraging Survival Data From Canfour Trial
Brief: Cantargia Reports Positive Results For CAN10 Antibody In Preclinical Systemic Sclerosis Model
Brief: Cantargia Reports Positive Results For CAN10 Antibody In Preclinical Systemic Sclerosis Model
Brief: Cantargia Says Oppositions Have Been Filed Against Co's Ep3293202 Patent
Brief: Cantargia Q3 Loss After Tax Widens To SEK 103.8 Million
Brief: Cantargia Gets Positive EMA Opinion For Orphan Designation Of Nadunolimab For Treatment Of Pancreatic Cancer
Brief: Cantargia's Extensive Patent Protection For IL1RAP-Targeting Cancer Therapy Maintained
Brief: Cantargia Receives Regulatory Approval To Start Trifour Study In Triple Negative Breast Cancer
Brief: Cantargia Completes Patient Recruitment To Phase IIa Pancreatic Cancer Extension Cohort In CANFOUR Study
Brief: Cantargia Receives Approval To Start Cestafour Clinical Study
Brief: Cantargia Reports Advantages Of Nadunolimab Mechanism Of Action
Brief: Cantargia Expands CIRIFOUR Trial
Brief: Cantargia Q2 Operating Loss Widens To SEK 86.6 Mln
Brief: Cantargia Broadens Development Of nadunolimab, Submits Application For Clinical Trial CESTAFOUR
Brief: Cantargia Q1 Loss After Tax Widens To SEK 72.6 Mln
Brief: Cantargia - Reports Positive Results In Ongoing Phase IIa Clinical Trial
Brief: Cantargia Presents New Preclinical Data